Wednesday, February 10, 2010, 3:17pm SGT - The Singapore stock market closes in 1 hour and 43 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEFINANCE NEWS
    Market:       |  

Talecris Biotherapeutics Holdings Corp. (TLCR)

At 5:00AM SGT: 22.50 USD  Down 0.05 (0.22%)  
 MORE ON TLCR 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Talecris Biotherapeutics Holdin (NasdaqNM:TLCR) Delayed quote dataEdit
After Hours: 22.50 0.00 (0.00%) as of 5:31am SGT on 02/10/10
Last Trade:22.50 USD
Trade Time:5:00AM SGT
Change:Down 0.05 (0.22%)
Prev Close:22.55
Open:22.50
Bid:21.82 x 100
Ask:N/A
1y Target Est:26.33
Day's Range:22.21 - 22.75
52wk Range:18.01 - 24.41
Volume:97,019
Avg Vol (3m):516,910
Market Cap:2.70B
P/E (ttm):11.90
EPS (ttm):1.89
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m 
 Add TLCR to Portfolio   Download Data

 HEADLINES 
Talecris Biotherapeutics Receives Orphan Drug Designation for Aerosolized Alpha1-Proteinase Inhibitor to Treat Alpha1-Antitrypsin Deficiency
Business Wire (Sat, Feb 6)
A Drugless Drugmaker IPO!
at Motley Fool (Fri, Feb 5)
Stephen Simpson Of Northland Securities Picks 4 Health Care Stock Winners For 2010
Wall Street Transcript (Thu, Jan 28)
HiSeq 2000 Genomics System Begins New Generation Of Innovation In DNA Sequencing Sector Of Biotech And Medical Diagnostics Industry
Wall Street Transcript (Tue, Jan 26)
After A Sluggish Year, VCs Eye Improvement
Investor's Business Daily (Sat, Jan 9)
Talecris Biotherapeutics to Present at the 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Sat, Jan 9)
PhRMA adds 7 biotech companies to its membership
AP (Sat, Jan 9)
Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations
Business Wire (Sat, Jan 9)
Coverage initiated on Talecris Biotherapeutics by BWS Financial
Briefing.com (Tue, Jan 5)
TALECRIS BIOTHERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Stat
EDGAR Online (Fri, Dec 18)
More Headlines for TLCR...

 ANALYST 
EPS Est (next year) (Dec-09) :1.36
EPS Est (in 2 years) (Dec-10) :1.54
Avg Rec (current)*:2.0
PEG Ratio:1.17
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Talecris Biotherapeutics Holdings Corp., a biotherapeutic and biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
Latest NewsSingapore Indices